ChemoCentryx, Inc. (CCXI): Price and Financial Metrics


ChemoCentryx, Inc. (CCXI): $66.23

0.36 (+0.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CCXI to Watchlist
Sign Up

Industry: Biotech


Ranked

of 318

in industry

CCXI Stock Summary

  • With a price/sales ratio of 64.59, ChemoCentryx Inc has a higher such ratio than 95.14% of stocks in our set.
  • With a year-over-year growth in debt of 197.35%, ChemoCentryx Inc's debt growth rate surpasses 93.29% of about US stocks.
  • Revenue growth over the past 12 months for ChemoCentryx Inc comes in at 99.3%, a number that bests 94.55% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to ChemoCentryx Inc, a group of peers worth examining would be CYCN, APTX, BLUE, ASMB, and BPMC.
  • Visit CCXI's SEC page to see the company's official filings. To visit the company's web site, go to www.chemocentryx.com.

CCXI Stock Price Chart Interactive Chart >

Price chart for CCXI

CCXI Price/Volume Stats

Current price $66.23 52-week high $70.29
Prev. close $65.87 52-week low $30.72
Day low $65.31 Volume 60,681
Day high $67.77 Avg. volume 474,130
50-day MA $62.27 Dividend yield N/A
200-day MA $57.45 Market Cap 4.58B

ChemoCentryx, Inc. (CCXI) Company Bio


ChemoCentryx, Inc. focuses on the discovery, development, and commercialization of orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. The company was founded in 1997 and is based in Mountain View, California.


CCXI Latest News Stream


Event/Time News Detail
Loading, please wait...

CCXI Latest Social Stream


Loading social stream, please wait...

View Full CCXI Social Stream

Latest CCXI News From Around the Web

Below are the latest news stories about ChemoCentryx Inc that investors may wish to consider to help them evaluate CCXI as an investment opportunity.

ChemoCentryx Appoints Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer

-- Brings more than two decades of executive management experience from global pharmaceutical companies -- MOUNTAIN VIEW, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer, reporting directly to President and Chief Executive Officer Thomas J. Schall, Ph.D. In this new capacity at ChemoCentryx, Tosh Butt will oversee many of the Company’s operational functions, and further strengthen the commercial infrastructure that ChemoCentryx has developed in anticipation of the launch of avacopan for the treatment of ANCA-associated vasculitis. A New Drug Application for avacopan is currently under review by the U.S. Food and Drug Administration, with a PDUFA g...

Yahoo | February 24, 2021

ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

-- Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group -- -- Avacopan’s effects on kidney function, patient Quality of Life, and reduction in overall glucocorticoid-related toxicities also described -- -- NDA for avacopan in ANCA-Associated Vasculitis is under review by the FDA with a PDUFA goal date of July 7, 2021 -- MOUNTAIN VIEW, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that The New England Journal of Medicine (NEJM) has published results from ADVOCATE, the pivotal Phase III study evaluating avacopan, an orally-administered selective complement 5a receptor inhibitor, for the treatment of patients with anti-n...

Yahoo | February 17, 2021

The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: COR...

Benzinga | February 10, 2021

The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25) Abbott Laboratories (NYSE: ABT ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) (announced FDA approval for its oral lupus nephritis drug) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioNano Genomics Inc (NASDAQ: BNGO ) (reacted to positive sell-side commentary) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearpoint Neuro Inc (NASDAQ: CLPT ) DarioHealth Corp (NASDAQ: DRIO ) DermTe...

Benzinga | January 26, 2021

Raymond James Stick to Their Buy Rating for Chemocentryx Inc. By Investing.com

Raymond James Stick to Their Buy Rating for Chemocentryx Inc.

Investing.com | January 8, 2021

Read More 'CCXI' Stories Here

CCXI Price Returns

1-mo 17.47%
3-mo 18.67%
6-mo 25.29%
1-year 49.91%
3-year 579.28%
5-year 1,906.97%
YTD 6.96%
2020 56.56%
2019 262.51%
2018 83.36%
2017 -19.59%
2016 -8.64%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9065 seconds.